Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMELLI P: Safety of SAR341402 vs NovoLog in CSII for T1DM
NCT03436498Phase 1Completed
- Sponsor
- Sanofi
- Start
- May 2018
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of insulin aspart in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Sanofi. Primary endpoint: Number of patients with infusion set occlusions at 4 weeks. Started May 2018; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03436498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03436498.